Actinium Pharmaceuticals awarded CEO Seth Sandesh 1,780,874 shares at $0 per share across two transactions on September 2. Afterward, Sandesh owned 1,965,355 shares and 1,130,400 derivative securities, giving investors the reported post-transaction ownership figures for the chief executive.

Key Highlights

  • Seth Sandesh held 1,965,355 Actinium Pharmaceuticals shares after the transactions.
  • Sandesh also owned 1,130,400 derivative securities following the award.
  • Both share transactions carried SEC transaction code A.

Actinium Pharmaceuticals, Inc. (AMEX: ATNM) awarded CEO Seth Sandesh 1,780,874 shares at $0 per share on September 2. The shares were awarded through two transactions, and Sandesh’s reported share ownership afterward was 1,965,355 shares.

Derivative Securities Were Reported Separately

Both share transactions used SEC transaction code A. On the same date, Sandesh was awarded 1,130,400 derivative securities in a transaction carrying the same code. His post-transaction ownership of derivative securities was 1,130,400. The filing reported the $0-per-share price for the 1,780,874 shares and separately reported the derivative securities. Sandesh is identified as Actinium Pharmaceuticals’ chief executive officer.